Intralesional infliximab in noninfectious cutaneous granulomas: Three cases of necrobiosis lipoidica

Dermatology

Volumn 222, Issue 3, 2011, Pages 213-216

  Barde, C ^a   Laffitte, E ^a   Campanelli, A ^a   Saurat, J H ^b   Thielen, A M ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Swiss Centre for Applied Human Toxicology   (Switzerland)

Author keywords

Infliximab, intralesional; Necrobiosis lipoidica, treatment; Ulcerations

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; PENICILLIN G; PENTOXIFYLLINE; PREDNISONE; RETINOID; STEROID; TACROLIMUS; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLOGRAFT; ARTICLE; AUTOGRAFT; CASE REPORT; DEBRIDEMENT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHATIC DRAINAGE; MILIARY TUBERCULOSIS; MULTIPLE CYCLE TREATMENT; NECROBIOSIS LIPOIDICA; PRIORITY JOURNAL; PUVA; REMISSION; SKIN GRAFT; STREPTOCOCCAL PHARYNGITIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND CARE; GRANULOMA; INTRALESIONAL DRUG ADMINISTRATION; MALE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; GRANULOMA; HUMANS; INJECTIONS, INTRALESIONAL; MALE; NECROBIOSIS LIPOIDICA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959955195     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000328403     Document Type: Article

References (20)

1. Peyrí J, Moreno A, Marcoval J: Necrobiosis lipoidica. Semin Cutan Med Surg 2007; 26: 87-89. (Pubitemid 46829958)
2. Ziegenhagen MW, Muller-Quernheim J: The cytokine network in sarcoidosis and its clin-ical relevance. J Intern Med 2003; 253: 18-30. (Pubitemid 36120994)
3. Ganesan S, Travis SP, Ahmad T, Jazrawi R: Role of tumor necrosis factor in Crohn's dis-ease. Curr Opin Investig Drugs 2002; 3:1297-1300. (Pubitemid 36266749)
4. Suárez-Amor O, Pérez-Bustillo A, Ruiz-González I, Rodríguez-Prieto MA: Necrobi-osis lipoidica therapy with biologicals: an ul-cerated case responding to etanercept and a review of the literature. Dermatology 2010; 221:117-121.
5. Klotz U, Teml A, Schwab M: Clinical phar-macokinetics and use of infliximab. Clin Pharmacokinet 2007; 46: 645-660.
6. Fayyazi A, Schweyer S, Eichmeyer B, Herms J, Hemmerlein B, Radzun HJ, Berger H: Expression of IFNgamma, coexpression of TNFalpha and matrix metalloproteinases and apoptosis of T lymphocytes and macro-phages in granuloma annulare. Arch Der-matol Res 2000; 292:384-390. (Pubitemid 30618104)
7. Zeichner JA, Stern DW, Lebwohl M: Treat-ment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006; 54(suppl 2):S120-S121. (Pubitemid 43243483)
8. Wallis RS, Broder M, Wong J, Lee A, Hoq L: Reactivation of latent granulomatous infec-tions by infliximab. Clin Infect Dis 2005; 41(suppl 3):S194-S198. (Pubitemid 41022090)
9. Heinzerling L, Dummer R, Kempf W, Schmid MH, Burg G: Intralesional therapy with anti-CD20 monoclonal antibody ritux-imab in primary cutaneous B-cell lympho-ma. Arch Dermatol 2000; 136: 374-378. (Pubitemid 30149111)
10. Biancone L, Cretella M, Tosti C, Palmieri G, Petruzziello C, Geremia A, Calabrese E, Pal-lone F: Local injection of infliximab in the postoperative recurrence of Crohn's disease. Gastrointest Endosc 2006; 63:486-492. (Pubitemid 43261480)
11. Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F: Treatment of perianal fistulas in Crohn's disease by local injection of anti-body to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand J Gastroenterol 2006; 41:1064-1072. (Pubitemid 44385064)
12. Swaminath A, Lichtiger S: Dilation of colon-ic strictures by intralesional injection of infliximab in patients with Crohn's colitis. Inflamm Bowel Dis 2008; 14:213-216. (Pubitemid 351288042)
13. Bokarewa M, Tarkowski A: Local infusion of infliximab for the treatment of acute joint inflammation. Ann Rheum Dis 2003; 62: 783-784. (Pubitemid 36886419)
14. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP: Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Oph-thalmol 2009; 147:825-830.
15. Svenson M, Geborek P, Saxne T, Bendtzen K: Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007; 46:1828-1834. (Pubitemid 350168300)
16. Cummins DL, Hiatt KM, Mimouni D Vander Kolk CA, Cohen BA, Nousari CH: Generalized necrobiosis lipoidica treated with a combination of split-thickness auto-grafting and immunomodulatory therapy Int J Dermatol 2004; 43: 852-854. (Pubitemid 39529950)
17. Zhang KS, Quan LT, Hsu S: Treatment of necrobiosis lipoidica with etanercept and adalimumab. Dermatol Online J 2009; 15:12.
18. Hu SW, Bevona C, Winterfield L, Qureshi AA, Li VW: Treatment of refractory ulcer-ative necrobiosis lipoidica diabeticorum with infliximab: report of a case. Arch Der-matol 2009; 145:437-439.
19. Kolde G, Muche JM, Schulze P, Fischer P, Li-chey J: Infliximab: a promising new treat-ment option for ulcerated necrobiosis li-poidica. Dermatology 2003; 206: 180-181. (Pubitemid 36205293)
20. Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA: Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg 2003; 7:382-386. (Pubitemid 37500396)